Johnson & Johnson stock holds near a 52-week high
Published on 08/22/2026 at 08:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Johnson & Johnson stock (US4781601046) closed at $270.24 on August 21, 2026 and finished that session up 1.07% at the New York close, while the shares ended just 2.21% below the 52-week high of $276.47. The stock also traded with a market value of $654.2 billion and volume of 2.38 million shares, keeping the company in a large-cap range that leaves little room for weak quarterly execution.
Revenue still sets the tone
The latest current operating context in the search results points to mid-single-digit revenue growth and a 2026 sales outlook that implies 7.3% growth, while the 2026 earnings estimate stands at $11.59 per share after a 30-day decline from $11.65. That mix matters because the share price now sits close to the year high, so even modest changes in the growth path can affect valuation quickly.
A recent FDA 510(k) clearance for MONARCH QUEST 3 update gives the medtech side a concrete product angle, and that kind of approval can help support the second-half setup for surgery, cardiovascular and vision-linked demand. The company also announced a cash dividend of $1.34 with an ex-date of August 25, 2026, which adds a dated capital-return marker to the near-term story.
What the market is pricing
At the latest close, Johnson & Johnson was trading at a trailing P/E ratio of 30.99 and a dividend yield of 1.96%. Compared with the 52-week low of $173.33, the stock was more than 55% higher, a gap that shows how much confidence the market already places in the current earnings stream.
For investors, the next point to watch is whether the company can convert that confidence into another quarter that supports the elevated multiple. If the 2026 earnings path keeps pace with the current estimate of $11.59, the stock can stay anchored near the upper part of its trading range.
MONARCH QUEST 3
MONARCH QUEST 3 is part of Johnson & Johnson's medtech push, where robotic-assisted procedures and related platform updates matter because they can widen the installed base and support recurring procedure volume. The product update is a useful reminder that the company's growth case is not tied to one pharmaceutical franchise alone.
Shares and dividend
Johnson & Johnson stock ended the latest session at $270.24 on August 21, 2026, with after-hours trading later showing $271.00. The shares remain close to the top of their 52-week range, and the August 25, 2026 ex-dividend date keeps income investors engaged even after the latest move.
Fact box
Company: Johnson & Johnson
ISIN: US4781601046
Ticker: JNJ
Exchange: NYSE
Price (as of August 21, 2026, 4:00 p.m. ET): $270.24 USD
Market cap: $654.2 billion
Sector / Industry: Health Care / Pharmaceuticals
Index membership: Dow Jones Industrial Average
Next earnings date: October 21, 2026
